

NHL: Mantle Cell Lymphoma Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: 0 0-E 0-X 0-XE IA IA-E IA-X IA-XE IB IB-E IB-X IB-XE IIA IIA-E IIA_X IIA-XE IIB IIB-E IIB-X IIB-XE
 IIIA IIIA-E IIIA-X IIIA-XE IIIB IIIB-E IIIB-X IIIB-XE IVA IVA-E IVA-X IVA-XE IVB IVB-E IVB-X IVB-XE NS
 Recurrent

Line of Treatment: First Line Second Line Third Line Third Line+ Maintenance

ECOG Performance Status: 0 1 2 3 4

Biomarker:

CD20 status: Negative Positive Not reported

HIV associated lymphoma: No Yes

Transplant candidate Non-transplant candidate

First Line Therapy | Transplant Candidate

Alternating R-CHOP/R-DHAP: cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, rituximab (Rituxan) alternating with dexamethasone, cisplatin (Platinol), cytarabine (Cytosar-U), and rituximab (Rituxan)

Nordic Regimen: dose-intensified rituximab (Rituxan), cyclophosphamide (Cytoxan), vincristine (Vincasar), doxorubicin (Adriamycin), prednisone, alternating with rituximab (Rituxan), and high-dose cytarabine (Cytosar-U)

First Line Therapy | Ineligible for transplant (not ASCT Candidate)

Bendamustine (Bendeka, Treanda) and rituximab (Rituxan)

Second and Subsequent Lines of Therapy

Bendamustine (Bendeka, Treanda) and rituximab (Rituxan)

Bortezomib (Velcade)

FCMR: fludarabine (Fludara), cyclophosphamide (Cytoxan), mitoxantrone (Novantrone), and rituximab (Rituxan)

Ibrutinib (Imbruvica)

Lenalidomide (Revlimid) *

* Following **two** prior therapies, including bortezomib

